FDA plans EHR database to target drug safety

FDA plans to use EHRs to find risk factors associated with adverse events to determine which drugs might require targeted warnings about their appropriate use.

The agency announced that current voluntary reporting of drug side effects is problematic. Some adverse side effects do not present themselves immediately. The submission forms are voluntary, and some individuals might not report adverse events. Plus, the complex forms can lead to inaccurate or incomplete reports.

FDA wrote on the Federal Business Opportunities website in December 2013 that it is seeking a partner to develop a database of de-identified EHR information. The database would allow the agency to assess risk factors including diagnoses, health history, hospitalizations and demographics.
 

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”